Traders should monitor upcoming catalysts: NDA submission for deucrictibant IR capsule (H1 2026) and topline data from CHAPTER-3 (Q3 2026), which are more likely to move the stock than this validation study.
Price Chart
Executive Summary
Pharvaris announced the publication of a real-world study validating patient-reported outcome measures (PGI and AMRA) used in clinical trials for on-demand treatment of hereditary angioedema (HAE), supporting the endpoint hierarchy in its ongoing Phase 3 RAPIDe-3 trial of deucrictibant. The findings reinforce the patient-centric design of the trial and may influence future HAE treatment assessments.
Key Facts
- Study validates PGI and AMRA instruments as reliable tools for assessing patient experience during HAE attacks.
- Findings support the hierarchical endpoint structure in the Phase 3 RAPIDe-3 trial of oral deucrictibant for on-demand HAE treatment.
- End of Progression™ was identified as the first meaningful milestone, followed by symptom relief and resolution.
- Deucrictibant has orphan drug designation in the U.S., EU, and Switzerland for bradykinin-mediated angioedema.
- NDA submission for deucrictibant immediate-release capsule expected in first half of 2026; CHAPTER-3 topline data expected Q3 2026.
Financial Impact
No direct financial impact disclosed; supports clinical development pathway without immediate revenue or cost implications.
Risk Factors
- Regulatory uncertainty regarding approval of deucrictibant despite validated endpoints.
- Clinical trial results may not replicate prior efficacy in larger studies.
- Competition from existing and emerging HAE therapies could limit market adoption.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3253609 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $38.06 $36.37 | ▲ +4.44% | ▲ +5.26% | $31.07 (+18.38%) |
Sep 14, 2026 17d ago | 144 | $38.06 $35.20 | ▼ −7.51% | ▼ −9.63% | $31.07 (−18.38%) |
Sep 14, 2026 18d ago | Insider Cluster | $38.86 $36.02 | ▼ −7.31% | ▼ −7.41% | $31.07 (−20.06%) |
Sep 11, 2026 21d ago | Insider Cluster | $38.02 $36.37 | ▼ −4.34% | ▼ −4.12% | $31.07 (−18.29%) |
Sep 8, 2026 24d ago | 6-K | $37.84 $38.86 | ▲ +2.70% | ▲ +3.36% | $31.07 (−17.90%) |
Aug 12, 2026 7w ago | 6-K | $36.46 $36.27 | ▼ −0.52% | ▼ −0.08% | $31.07 (−14.80%) |
Aug 12, 2026 7w ago | Press Release | $36.46 $36.27 | ▼ −0.52% | ▼ −0.08% | $31.07 (−14.80%) |
Aug 6, 2026 8w ago | Press Release | $34.45 $34.04 | ▼ −1.19% | ▼ −2.40% | $31.07 (−9.83%) |
Jul 6, 2026 12w ago | Press Release | $33.22 $35.07 | ▲ +5.57% | ▲ +5.08% | $31.07 (−6.49%) |
Jul 1, 2026 13w ago | Insider Cluster | $33.86 $35.96 | ▲ +6.20% | ▲ +5.27% | $31.07 (−8.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access